Procter, Gamble and Alimentary Health Ltd. | Date: 2016-08-26
Agency: Cordis | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-2011-IAPP | Award Amount: 1.06M | Year: 2011
The essence of this proposal is to establish a collaborative training network which will develop novel immune-regulatory molecules from Bifidobacterium infantis 35624, for treatment of inflammatory diseases. A multidisciplinary team of four prestigious European partners has been assembled (SME & Coordinator - Alimentary Health Ltd (expert in developing probiotic products); Swiss Institute for Asthma and Allergy Research, (expert in immune-regulation); Vienna Institute of Biotechnology at Universitt fr Bodenkultur (expert in glycobiology); and University College Cork, Alimentary Pharmabiotics Centre and Department of Microbiology (expert in bioinformatics and glycobiology assembly in probiotic bacteria). Each partner will provide unique critical expertise, through knowledge, personnel and facilities which will be complementary and additive and will provide the synergistic expertise required to successfully deliver on the goal of this project and forge a long-lasting relationship. The end result: a unique opportunity for cross-sector state-of-the-art knowledge transfer and dissemination, through the identification of molecules from B. infantis 35624 with proven efficacy in the treatment of IBS and other inflammatory conditions expected to have major commercialization, economic and health implications. B. infantis 35624 is a commensal micro-organism, originally isolated from human gastrointestinal tissue, which has demonstrated unique properties in human clinical studies. B. infantis 35624 consumption is associated with significant improvement in the composite score for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty compared with placebo in two appropriately designed studies. No other bacterial strain has shown significant improvement in Irritable Bowel Syndrome (IBS) symptoms. The exact mechanisms underpinning the clinical benefit are not known but modulation of the host immune response is strongly believed to play a role.
University College Cork, Alimentary Health Ltd. and Teagasc | Date: 2013-03-27
The current invention provides use of a CLA-producing bacterium for the in vivo conversion in the gut of polyunsaturated fatty acids to CLA. The CLA-producing bacterium is selected from one or more of the group consisting of propionibacteria, lactobacilli, lactococci and streptococci, and bifidobacteria.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: KBBE.2013.2.2-02 | Award Amount: 13.01M | Year: 2013
Emerging evidence indicates that the gut microbiome contributes to our ability to extract energy from the diet and influences development and function of the immune, endocrine and nervous systems, which regulate energy balance and behaviour. This has led to hypothesize that developing microbiome-based dietary interventions can be cost-effective measures to prevent diet-related and behavioural disorders. Yet this approach is restricted in practice by a lack of understanding of the specific species that contribute to these disorders and their interactions with host and lifestyle determinants. To progress beyond the state of the art, the MyNewGut proposal aims to: (1) shed light on the contribution of the human microbiome to nutrient metabolism and energy expenditure; (2) identify microbiome-related features that contribute to or predict obesity and associated disorders in human epidemiological studies; (3) understand how the microbiome is influenced by environmental factors and its role in brain and immune development and function in humans; and (4) provide proof-of-concept of the disease risk-reduction potential of dietary intervention with new foods/ingredients targeting the gut microbiome in humans. To this end, a translational multidisciplinary research strategy will be developed, combining experts in omic-technologies and all other scientific disciplines required. Consequently, the MyNewGut proposal will contribute to developing new approaches to prevent diet-related diseases (metabolic syndrome and obesity) and behavioural disorders through lifestyle changes, intake of pro- and prebiotics and semi-personalised and innovative food products. This will ultimately contribute to increasing the competitiveness of the European food industry and provide consumers with reliable claims on foods. Results will also help inform new strategies on public health, support EU legislation and improve the position of the EU in the field of food-related disease prevention.
Alimentary Health Ltd, Procter and Gamble | Date: 2013-01-10
An isolated polysaccharide has the structure [-(1,3)-D-GaIpNAc-(1,4)-D-Glcp-]_(n). The polysaccharide may be from a Bifidobacterium strain NCIMB 41003. The polysaccharide exhibits immunomodulatory activity.
Procter, Gamble and Alimentary Health Ltd | Date: 2011-04-13
The use of orally administered, selected Bifidobacteria for regulating the cosmetic appearance of human skin, such as for reducing wrinkles and fine lines.
The Iams Company and ALIMENTARY HEALTH Ltd | Date: 2014-10-17
According to the present invention there are provided methods of use in companion animals of probiotic bacteria of the genus Bifidobacteria.
The IAMS Company and Alimentary Health Ltd | Date: 2011-01-05
According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.
ALIMENTARY HEALTH Ltd | Date: 2014-03-18
Probiotic Bifidobacterium strain AH1205 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity such as undesirable gastrointestinal inflammatory activity for example inflammatory bowel disease.
Alimentary Health Ltd, Procter and Gamble | Date: 2015-01-14
Bifidobacterium strain AH121A is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.